Biomarin Pharmaceutical Inc
BMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001048477
In the last 90 days, Biomarin Pharmaceutical Inc insiders filed 0 open-market purchases and 1 sale; 568 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $11.1B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.16M in total
- 1
- 13F holdersQ2 2026, +10 vs. previous quarter
- 568
- 13F valueReported value at the end of Q2 2026
- $11.1B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $3.22B
- +12.9% year over year
- Net income, FY2025
- $348.9M
- −18.3% year over year
- Free cash flow, FY2025
- $725.0M
- +48.7% year over year
- Revenue, Q3 FY2026
- $1.02B
- +32.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 14.1M
- Shares sold short
- Change
- +2.07M
- +17.2% vs. previous
- Days to cover
- 5.77
- At average daily volume
Superinvestors holding BMRN, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Biomarin Pharmaceutical Inc on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
1.2%
Biomarin Pharmaceutical Inc's share of the portfolio
- Shares
- 7,616,563
- Value
- $435.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Biomarin Pharmaceutical Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)6:41 PM ET | Sep 2 | 1 day | Davis George EricEVP, Chief Legal Officer | SSale | −17.6K | $66.28 | −$1.16M | −22.3%61.0K after | |
| May 11, 2026 (view filing) | May 7 | 4 days | Friberg Gregory REVP, Chief R&D Officer | SSale | −3.28K | $53.85 | −$176.7K | −6.0%51.8K after | |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Guyer Charles GregEVP, Chief Technical Officer | SSale | −16.5K | $60.46 | −$996.7K | −17.1%80.0K after | |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Friberg Gregory REVP, Chief R&D Officer | SSale | −6.33K | $60.38 | −$382.0K | −14.4%37.6K after | |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Davis George EricEVP, Chief Legal Officer | SSale | −26.1K | $61.36 | −$1.60M | −26.5%72.5K after | |
| May 20, 2025 (view filing) | May 20 | Same day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.79K | $59.31 | −$105.9K | −11.2%14.2K after | 10b5-1 |
| May 6, 2025 (view filing) | May 2 | 4 days | Hubbard CristinEVP, Chief Commercial Officer | SSale | −273 | $64.92 | −$17.7K | −0.8%32.7K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 19 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.29K | $71.52 | −$92.6K | −7.1%17.0K after | 10b5-1 |
| Mar 7, 2025 (view filing) | Mar 6 | 1 day | Guyer Charles GregEVP, Chief Technical Officer | SSale | −7.03K | $71.28 | −$501.4K | −7.4%87.7K after | |
| Feb 25, 2025 (view filing) | Feb 24 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.34K | $68.38 | −$91.9K | −9.3%13.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 568 holdersThe largest institutional positions in Biomarin Pharmaceutical Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,445,212 | $1.17B | 0.02% | +626,911+3.2% | Added |
| Dodge & Cox | 14,844,930 | $849.4M | 0.44% | +283,171+1.9% | Added |
| Primecap Management Co | 14,190,183 | $812.0M | 0.48% | −3,8220.0% | Reduced |
| Vanguard Capital Management LLC | 8,743,633 | $500.3M | 0.01% | +100,469+1.2% | Added |
| Vanguard Portfolio Management LLC | 8,648,678 | $494.9M | 0.02% | +350,203+4.2% | Added |
| Norges Bank | 8,207,954 | $469.7M | 0.05% | +8,207,954 | New |
| State Street Corp | 7,800,959 | $446.4M | 0.01% | +505,880+6.9% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 7,616,563 | $435.8M | 1.24% | +554,486+7.9% | Added |
| Vestal Point Capital, LP | 6,025,000 | $344.8M | 8.06% | +2,450,000+68.5% | Added |
| AQR Capital Management LLC | 5,699,541 | $322.5M | 0.11% | −1,977,000−25.8% | Reduced |
Holders of 5% or more of BMRN
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Biomarin Pharmaceutical Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 10.00%19.4M shares | +0.90 ppfrom 9.10% | Apr 29, 20253 filings | Nov 4, 2026 | SEC |
| Primecap Management Co | 13G/A | 8.24%15.8M shares | – | Jan 7, 20216 filings | Aug 14, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 5.25%10.1M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in BMRN3 members of Congress reported 7 trades in Biomarin Pharmaceutical Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Apr 17, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
| Nov 15, 2021 |  Josh Gottheimer House · NJ | Sell | $1K-$15K |
| Jan 11, 2021 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $15K-$50K |
| Nov 5, 2020 | Josh Gottheimer House · NJ | Buy | $1K-$15K |
| Oct 13, 2020 | Josh Gottheimer House · NJ | Sell | $1K-$15K |
House · NY · Apr 17, 2023
Sell$1K-$15K
House · NJ · Nov 15, 2021
Sell$1K-$15K
House · CA · Jan 11, 2021
Buy$15K-$50K
House · NJ · Nov 5, 2020
Buy$1K-$15K
House · NJ · Oct 13, 2020
Sell$1K-$15K